The Oncomine Dx Target Test assesses tumor samples for the presence of biomarkers associated with three drug therapies approved to treat non-small cell lung cancer.
Physicians can use the test to identify the ideal therapy option for each patient, based on his or her own biomarkers.
Thermo Fisher Scientifics will roll out the test to several laboratories across the country, including Burlington N.C.-based LabCorp; Fort Myers, Fla.-based NeoGenomics Laboratories; and Rutherford, N.J.-based Cancer Genetics.
More articles on supply chain:
Viewpoint: 4 insights into postapproval monitoring of medical devices
6 drugmakers in the headlines
Philips acquires noninvasive neurodiagnostics company for $36M
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.